Evaluating whether ABEO is a sound investment requires balancing its promising rare-disease gene therapy pipeline against the typical high volatility and clinical risks associated with commercial-stage biotechnology equities. Investors are advised to examine current cash burn rates, regulatory progress, and individual risk tolerances before purchasing shares.